High cholesterol medication
Pro Research Analysisby 
Searched over 200M research papers
High Cholesterol Medication: Efficacy, Safety, and Trends
Statins: The Cornerstone of Cholesterol-Lowering Therapy
Prevalence and Usage Trends
Statins are the most commonly prescribed medications for lowering cholesterol. Between 2003 and 2012, the use of prescription cholesterol-lowering medications among adults aged 40 and over increased significantly, with statins being the predominant choice . By 2011-2012, 83% of adults using cholesterol-lowering medications were on statins alone, with simvastatin and atorvastatin being the most frequently used .
Efficacy and Safety
Statins are highly effective in reducing low-density lipoprotein cholesterol (LDL-C) and have been shown to significantly reduce the risk of cardiovascular events . The 2013 cholesterol treatment guidelines emphasize the use of statins based on LDL-C levels and cardiovascular risk factors . Despite their widespread use, statins are underutilized due to factors such as lack of awareness, fear of side effects, and cost .
Alternative and Adjunctive Therapies
Fibrates and Niacin
Fibrates and niacin are other classes of medications used to manage cholesterol levels. Fibrates primarily reduce triglycerides and increase high-density lipoprotein cholesterol (HDL-C), while niacin has a more potent effect on raising HDL-C . Both have been shown to reduce the risk of major coronary events, with fibrates reducing the risk by 25% and niacin by 27% . However, the use of niacin is often limited by side effects such as flushing .
Mipomersen
Mipomersen, an antisense inhibitor of apolipoprotein B synthesis, has shown promise in patients with homozygous familial hypercholesterolemia, a condition characterized by extremely high LDL-C levels . In a randomized, double-blind, placebo-controlled trial, mipomersen significantly reduced LDL-C levels by 24.7% compared to placebo . However, it is associated with injection-site reactions and elevated liver enzymes .
Inclisiran
Inclisiran, a small interfering RNA targeting PCSK9, has demonstrated sustained reductions in LDL-C levels in patients at high cardiovascular risk . In a phase 2 trial, inclisiran reduced LDL-C levels by up to 52.6% with two doses, and the effects were maintained for up to 240 days . Inclisiran was generally well-tolerated, with injection-site reactions being the most common adverse event .
ETC-1002 (Bempedoic Acid)
ETC-1002, also known as bempedoic acid, is an oral medication that has shown efficacy in lowering LDL-C levels, both alone and in combination with ezetimibe . In a phase 2b trial, ETC-1002 reduced LDL-C by up to 30% as monotherapy and by up to 48% when combined with ezetimibe . It was well-tolerated, with similar rates of muscle-related adverse events in both statin-intolerant and statin-tolerant patients .
CETP Inhibitors
Cholesteryl ester transfer protein (CETP) inhibitors, such as torcetrapib, have been investigated for their ability to raise HDL-C levels . While CETP inhibitors significantly increase HDL-C, their impact on cardiovascular outcomes has been disappointing. A meta-analysis found no significant effect on all-cause mortality, coronary heart disease mortality, myocardial infarction, or stroke . This suggests that simply raising HDL-C levels may not translate into reduced cardiovascular events, especially in the era of widespread statin use .
Conclusion
While statins remain the cornerstone of cholesterol-lowering therapy due to their proven efficacy and safety, alternative and adjunctive therapies such as fibrates, niacin, mipomersen, inclisiran, and ETC-1002 offer additional options for patients with specific needs or intolerances. However, the clinical benefits of raising HDL-C pharmacologically remain uncertain, highlighting the complexity of lipid management in cardiovascular disease prevention.
Sources and full results
Most relevant research papers on this topic